Home
About
Overview
Sharing Data
ORCID
Help
History (28)
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies.
Bucladesine
Solanum glaucophyllum
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer.
See All 28 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer.
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. J Thorac Oncol. 2016 09; 11(9):1381-3.
View in:
PubMed
subject areas
Exons
Humans
Lung Neoplasms
Mutation
authors with profiles
Ravi Salgia